DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)

More documents

Recommendations

Info

12 OxyContin ® tablets When osteoarthritis oa pain is controlled, o life begins. 1 OxyContin ® tablets provide long-acting relief from moderate to severe chronic osteoarthritis pain. 1,2 * FULLY FUNDED PHARMACEUTICAL SCHEDULE OxyContin ® tablets should be used as part of a multi-modal pain management plan, not in isolation. *CONTROLLED DRUG B3 – For the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. OxyContin ® tablets – oxycodone hydrochloride Presentation Oxycodone hydrochloride 5mg, 10mg, 20mg, 40mg, 80mg controlled release tablets is a Controlled Drug Class B3. Indication The management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. Dosage and Administration Must be swallowed whole and not broken, chewed or crushed. Taking broken, chewed or crushed OxyContin ® tablets could lead to the rapid release and absorption of a potentially toxic dose of oxycodone. Alcohol should be avoided while the patient is being treated with OxyContin ® tablets. Adults, elderly and children over 12 years: Dose at 12-hourly intervals. Usual starting dose (opioid-naïve patients or patients with severe pain uncontrolled by weaker opioids): one OxyContin ® 10mg tablet 12-hourly. Patients with renal or hepatic impairment: one OxyContin ® 5mg tablet 12-hourly. Titrate carefully (once a day if required) to achieve pain relief. 10mg oral oxycodone is equivalent to 20mg oral morphine. OxyContin ® 80mg tablets should only be used in opioid-tolerant patients. Children: Not recommended in children under 12 years of age. Contraindications Hypersensitivity to opioids or to any constituents of OxyContin ® tablets, acute respiratory depression, cor pulmonale, cardiac arrhythmias, acute asthma or other obstructive airways disease, paralytic ileus, suspected surgical abdomen, severe hepatic impairment, delayed gastric emptying, acute alcoholism, brain tumour, increased cerebrospinal or intracranial pressure, head injury, severe CNS depression, convulsive disorders, delirium tremens, hypercarbia, concurrent administration of monoamine oxidase inhibitors (MAOIs) or within 2 weeks of discontinuation of their use, pregnancy. Not recommended for pre-operative use or for the first 24 hours post-operatively. Warnings and Precautions The major risk of opioid excess is respiratory depression. Use with caution in patients with hypothyroidism (may need to reduce dose), debilitated elderly or infirm patients, opioid dependence, hypotension, hypovolaemia, diseases of the biliary tract, pancreatitis, inflammatory bowel disorders, prostatic hypertrophy, adrenocortical insufficiency (Addison’s disease), toxic psychosis, chronic pulmonary, renal or hepatic disease, myxoedema, following abdominal surgery, chronic, non-malignant pain, a prior history of substance abuse. Discontinue use if paralytic ileus is suspected or occurs. As with other opioids, tolerance and physical dependence tend to develop upon repeated administration of oxycodone. There is potential for abuse of the medicine and for development of strong psychological dependence. OxyContin ® tablets should therefore be prescribed and handled with a high degree of caution appropriate to the use of a medicine with strong abuse potential. Not recommended in pregnancy (Category C), lactation. Tolerance and physical dependence tend to develop upon repeated administration. Withdraw gradually. Parenteral venous injection of the tablet constituents may be fatal. May affect driving or operating machinery. Do not use in immediate pre-operative period, or within 24 hours of cordotomy or other pain-relieving surgery. Special Risk Groups: Reduce dosage in elderly, debilitated patients and in patients with renal impairment or hepatic impairment (1/3 to 1/2 of usual starting dose). Adverse Effects Adverse medicine reactions are typical of full opioid agonists. Gastrointestinal disorders abdominal pain, constipation, diarrhoea, nausea, dry mouth, dyspepsia, vomiting; General disorders asthenia, chills; Hepatobiliary disorders cholestasis, increased hepatic enzymes; Metabolic and nutritional disorders anorexia; Nervous System disorders dizziness, headache, somnolence; Psychiatric disorders anxiety, confusional state, insomnia, nervousness, thinking abnormal; Respiratory, Thoracic and Mediastinal disorders dyspnoea, respiratory depression; Skin and Subcutaneous Tissue disorders hyperhidrosis, pruritus, rash. Interactions Anticholinergic agents, antihypertensive agents, CNS depressants (including sedatives or hypnotics, general anaesthetics, phenothiazines, other tranquillisers, alcohol, other opioids and neuroleptic medicines, etc), coumarin derivatives, metoclopramide, monoamine oxidase inhibitors (MAOIs), neuromuscular blocking agents, opioid agonist analgesics (including morphine, pethidine), opioid agonist-antagonist analgesics (including pentazocine, butorphanol, buprenorphine). Metabolic interactions with medicines that involve the cytochrome P450 enzyme system (CYP3A4, CYP2D6). Pharmaceutical Schedule Fully funded. Standard prescription charge applies. Distributed on behalf of Mundipharma New Zealand Limited by: Pharmaco (NZ) Ltd, P O Box 4079, AUCKLAND Ph: (09) 377-3336 Toll Free (Medical Enquiries): 0800 773 310 Fax: (09) 307 1307 Data Sheet: 21 May 2010 ®: OXYCONTIN is a Registered Trademark. For further information and prior to prescribing please refer to the manufacturer’s Data Sheet available on the Medsafe website www.medsafe.govt.nz ORBIS NZ-0091 DA1211AY MP5518 May 2011 References 1. Roth SH et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain. Arch Intern Med 2000,160:853-860. 2. OxyContin ® tablets Data Sheet, May 2010.
Thursday 09th June 13 Thurs 09th June 0830-1030 WORKSHOPS Preliminary Day Workshops are repeated content not part 1 and 2 unless otherwise stated WS 1 WS 2 WS 3 WS 4 WS 5 WS 6 WS 7 Level 7 ALS Basic Surgery 1 Zac Moaveni Peter Chapman- Smith MAS Business Summit HR and Financial Management 1 Chris Wills Shaun Phelan Vasectomy 1 Bruce Sutherland IT Symposium Andrew Kissling Ross Boswell Tom Bowden Cornelius Dirven David Hay Sanjeewa Samaraweera Medicolegal Forum 1 Peter Robinson Gaeline Phipps Musculoskeletal Medicine 1 Ian Wallbridge Rick Bernau Keith Laubscher 1030-1100 MORNING TEA WS 8 WS 9 WS 10 WS 11 WS 12 1100-1300 Advanced Surgery 1 Zac Moaveni Peter Chapman- Smith MAS Business Summit HR and Financial Management Cont. Vasectomy 2 Bruce Sutherland IT Symposium Cont. Medicolegal Forum 2 Peter Robinson Gaeline Phipps Musculoskeletal Medicine 2 Ian Wallbridge Rick Bernau Keith Laubscher Dermoscopy 1 4hr session Amanda Oakley Dermoscopy 1 Cont. Opus Sovereign Sigma Picasso Monet Works Skellerup 1300-1400 LUNCH WS 13 WS 14 WS 15 WS 16 WS 17 WS 18 WS 19 1400-1600 Basic Surgery 2 Zac Moaveni Peter Chapman- Smith MAS Business Summit HR and Financial Management 2 Diabetes WS Kingsley Nirmalaraj Rab Burtun Antenatal care in GP 1 Deralie Flower Ngaire Anderson Managing Somatisation in GP 1 Brett Mann New Vaccines 1 Pneumococcus, Rotavirus, Varicella Neil Poskitt Stewart Reid Monet 1600-1630 AFTERNOON TEA WS 20 WS 21 WS 22 WS 23 1630-1830 Opus Opus Advanced Surgery 2 Zac Moaveni Peter Chapman- Smith Opus Sovereign Sovereign MAS Business Summit HR and Financial Management 2 Cont. Sovereign Sigma Works Diabetes WS Cont. Works Picasso Sigma Antenatal care in GP 2 Deralie Flower Ngaire Anderson Sigma Monet Picasso Managing Somatisation in GP 2 Brett Mann Picasso Works New Vaccines 1 Pneumococcus, Rotavirus, Varicella Neil Poskitt Stewart Reid Monet Skellerup Dermoscopy 2 4hr session Amanda Oakley Skellerup Dermoscopy 2 Cont. Skellerup ALS Course Level 7 (8 hours) Conference ALS Course Level 7 Cont. Conference ALS Course Level 7 Cont. Conference ALS Course Level 7 Cont. Conference 8 10 6 5 7 4 9 3 2 EXHIBITION 11 1 12 13 1 Registration Desk 8 Picasso 2 Sovereign 9 Van Gogh 3 Skellerup 10 Kandinsky 4 Opus 11 Baytrust (Main Plenary Room) 5 Works 12 Sportsdrome (Practice Managers & Practice Nurses Programmes) 6 Sigma 13 Conference Room (ALS Courses) 7 Monet 09-12 June 2011 | Energy Events Centre | Rotorua
Page 1 and 2: www.gpcme.co.nz 09-12 June 2011 | E
Page 3 and 4: Welcome Welcome again to Rotorua. W
Page 5 and 6: Contents EXHIBITION SECTION 1 Map o
Page 7 and 8: Rotorua Map 3 Rotorua Map Useful Co
Page 9 and 10: Exhibition Listing 5 Exhibitor List
Page 11 and 12: Companies By Product 7 ADHD 44-46 -
Page 13 and 14: Prizes & Competitions 9 Tear along
Page 15: Prizes & Competitions 11 Exhibitor
Page 19 and 20: Friday 10th June 15 Friday 10th Jun
Page 21 and 22: Saturday 11th June 17 Saturday 11th
Page 23: Saturday 12th June 19 Saturday 11th
Page 26 and 27: 22 Caring for the lives of millions
Page 28 and 29: 24 Biographies & Sessions Dr Brian
Page 30 and 31: 26 Biographies & Sessions Dr David
Page 32 and 33: 28 To find out more about visit us
Page 34 and 35: 30 Biographies & Sessions Mr Andrew
Page 36 and 37: 32 Biographies & Sessions Marijke C
Page 38 and 39: 34 Biographies & Sessions Dr Helen
Page 41 and 42: Speakers Biographies Dr Colin Edwar
Page 43 and 44: Biographies & Sessions 39 Speakers
Page 46 and 47: 42 Your osteoporosis patients now h
Page 48 and 49: 44 Biographies & Sessions Dr Paula
Page 50 and 51: 46 Biographies & Sessions Dr Edward
Page 52 and 53: 48 Biographies & Sessions Dr Kevin
Page 54 and 55: 50 Biographies & Sessions Dr Alasda
Page 56 and 57: 52 Biographies & Sessions Mr Grant
Page 58 and 59: 54 Biographies & Sessions Dr Matthi
Page 60 and 61: 56 Biographies & Sessions Dr Tim Su
Page 62 and 63: 58 Ensure you know of all recommend
Page 64 and 65: 60 Pre-Conference Workshop Thursday
Page 66 and 67:
62 Pre-Conference Workshop Thursday
Page 68 and 69:
64 Wound Management Casting Needles
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
70 CanberraHealth Cooperative Aust
Page 76 and 77:
72 Main Programme Friday 10th June
Page 78 and 79:
74 Time for baby talk! Chat to one
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
80
Page 86 and 87:
82 Clinically proven* to reduce Ins
Page 88 and 89:
Page 90 and 91:
86 Practice Managers Programme Frid
Page 92 and 93:
88 Practice Managers Programme Frid
Page 94 and 95:
90 MOVICOL ® macrogol 3350 plus el
Page 96 and 97:
92 Main Programme Saturday 11th Jun
Page 98 and 99:
94 New Zealand’s most prescribed
Page 100 and 101:
96 Main Programme Saturday 11th Jun
Page 102 and 103:
98 The Most Recommended Expectorant
Page 104 and 105:
100 Main Programme Saturday 11th Ju
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
116 Healthier Communities through A
Page 122 and 123:
118 Practice Nurses Programme Satur
Page 124 and 125:
120
Page 126 and 127:
122 Main Programme Sunday 12th June
Page 128 and 129:
124 Visit Roche Products at stand 3
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
132 Delegate Listings as of 24 May
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
152 GP CME 2012 General Practice Co
Page 158 and 159:
Saturday 11th June 2011 MAIN CONFER
Page 160 and 161:
156 Exhibitor Directory Bayer Healt
Page 162 and 163:
158 Exhibitor Directory DrInfo ....
Page 164 and 165:
160 Exhibitor Directory Johnson & J
Page 166 and 167:
162 Exhibitor Directory New Zealand
Page 168 and 169:
164 Exhibitor Directory Roche Diabe
Page 170 and 171:
166 NO SPECIAL AUTHORITY Help your
Page 172:
168 PLATINUM SPONSOR A Promise for
show all

DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?